AGC Biologics proposes 126K-square-foot expansion to Boulder facility

BOULDER — Biopharmaceutical company AGC Biologics is planning a more than 126,000-square-foot expansion to its manufacturing facility at 5550 Airport Blvd., according to planning documents filed with the city.

The existing plant is about 178,000 square feet. The expansion would feature a 126,480-square-foot two-story manufacturing space and 188 new spaces in the parking lot. It would also include new standalone electrical and waste buildings, respectively 2,180 and 3,000 square feet, and a 28,000-cubic-foot expansion of its detention pond. 

AGC Biologics acquired the building for $39.7 million from AstraZeneca in 2020, according to Boulder County property records. It has not yet begun production at the facility. According to planning documents, commercial manufacturing is slated to begin in early 2022 with the Thyroid Eye Disease drug Tepezza for client Horizon Therapeutics. The expansion will allow AGC to manufacture ingredients for the Novavax COVID-19 vaccine at the Boulder facility. 

At its current size, AGC’s Boulder space can support 250 to 270 employees. The expansion will increase that to 320 to 350 employees, according to planning documents. 

AGC Biologics is headquartered in Bothell, Washington. It also has facilities in Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy and Ichihara City, Japan. 

© 2021 BizWest Media LLC

on Facebook on LinkedIn